Synergistic anticancer effect of cisplatin and Chal-24 combination through IAP and c-FLIPL degradation, Ripoptosome formation and autophagy-mediated apoptosis

Oncotarget

Volumn 6, Issue 3, 2015, Pages 1640-1651

  Shi, Shaoqing ^a,b   Wang, Qiong ^b,c   Xu, Jennings ^b   Jang, Jun Ho ^b,d   Padilla, Mabel T ^b   Nyunoya, Toru ^b,d   Xing, Chengguo ^e   Zhang, Lin ^a,c   Lin, Yong ^b  

^a SICHUAN UNIVERSITY   (China)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c SICHUAN UNIVERSITY   (China)

^d NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Apoptosis; Autophagy; C FLIP; C IAP; Chal 24; Cisplatin

Indexed keywords

ANTINEOPLASTIC AGENT; BECLIN 1; CARRIER PROTEINS AND BINDING PROTEINS; CASPASE 8; CHAL 24; CHALCONE DERIVATIVE; CISPLATIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; RECEPTOR INTERACTING PROTEIN 1; RIPOPTOSOME COMPLEX; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; 3-(3-HYDROXY-4-METHOXYPHENYL)-1-(3,4,5-TRIMETHOXYPHENYL)PROP-2-EN-1-ONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LUNG CANCER CELL LINE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; DRUG EFFECTS; DRUG RESISTANCE; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; CHALCONES; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84922757331     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2746     Document Type: Article

References (48)

1. Seve P, Dumontet C. Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents. 2005; 5:73-88.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
3. Lonning PE. Molecular basis for therapy resistance. Mol Oncol. 2010; 4:284-300.
4. Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ, Los M. Apoptosis and cancer: mutations within caspase genes. J Med Genet. 2009; 46:497-510.
5. Ocker M, Hopfner M. Apoptosis-modulating drugs for improved cancer therapy. Eur Surg Res. 2012; 48:111-120.
6. Fulda S. Tumor resistance to apoptosis. Int J Cancer. 2009; 124:511-515.
7. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes?. Acta Pharmacol Sin. 2008; 29:1275-1288.
8. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003; 3:745-756.
9. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 2011; 71:3-10.
10. Wang G, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep. 2004; 12:955-965.
11. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, Cain K, MacFarlane M, Hacker G, Leverkus M. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Molecular Cell. 2011; 43:449-463.
12. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, Zachariou A, Lopez J, MacFarlane M, Cain K, Meier P. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Molecular Cell. 2011; 43:432-448.
13. Bertrand MJ, Vandenabeele P. The Ripoptosome: death decision in the cytosol. Molecular Cell. 2011; 43:323-325.
14. Todde V, Veenhuis M, van der Klei IJ. Autophagy: principles and significance in health and disease. Biochim Biophys Acta. 2009; 1792:3-13.
15. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011; 147:728-741.
16. Srinivasan B, Johnson TE, Lad R, Xing C. Structureactivity relationship studies of chalcone leading to 3-hydroxy-4,3',4',5'-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities. Journal of Medicinal Chemistry. 2009; 52:7228-7235.
17. He W, Wang Q, Srinivasan B, Xu J, Padilla MT, Li Z, Wang X, Liu Y, Gou X, Shen HM, Xing C, Lin Y. A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy. Oncogene. 2014; 33:3004-3013.
18. Warmka JK, Solberg EL, Zeliadt NA, Srinivasan B, Charlson AT, Xing C, Wattenberg EV. Inhibition of mitogen activated protein kinases increases the sensitivity of A549 lung cancer cells to the cytotoxicity induced by a kava chalcone analog. Biochemical and Biophysical Research Communications. 2012; 424:488-492.
19. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene. 2008; 27:6252-6275.
20. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K, Fairbrother WJ, Vucic D. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. The Journal of Biological Chemistry. 2008; 283:24295-24299.
21. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M, Tergaonkar V, Schneider P, Callus BA, Koentgen F, et al. IAP Antagonists Target cIAP1 to Induce TNFalpha-Dependent Apoptosis. Cell. 2007; 131:682-693.
22. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008; 133:693-703.
23. Darding M, Meier P. IAPs: guardians of RIPK1. Cell Death and Differentiation. 2012; 19:58-66.
24. Loder S, Fakler M, Schoeneberger H, Cristofanon S, Leibacher J, Vanlangenakker N, Bertrand MJ, Vandenabeele P, Jeremias I, Debatin KM, Fulda S. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia. 2012; 26:1020-1029.
25. Imre G, Larisch S, Rajalingam K. Ripoptosome: a novel IAP-regulated cell death-signalling platform. J Mol Cell Biol. 2011; 3:324-326.
26. Abedini MR, Muller EJ, Brun J, Bergeron R, Gray DA, Tsang BK. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Research. 2008; 68:4511-4517.
27. Ding L, Yuan C, Wei F, Wang G, Zhang J, Bellail AC, Zhang Z, Olson JJ, Hao C. Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Investigation. 2011; 29:511-520.
28. Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, Hemann MT. Defining principles of combination drug mechanisms of action. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:E170-179.
29. Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nature Reviews Drug Discovery. 2009; 8:111-128.
30. Stordal B, Pavlakis N, Davey R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treatment Reviews. 2007; 33:688-703.
31. Wu WK, Coffelt SB, Cho CH, Wang XJ, Lee CW, Chan FK, Yu J, Sung JJ. The autophagic paradox in cancer therapy. Oncogene. 2011; 31:939-953.
32. Kreuzaler P, Watson CJ. Killing a cancer: what are the alternatives?. Nat Rev Cancer. 2012; 12:411-424.
33. Blagosklonny MV. Unwinding the loop of Bcl-2 phosphorylation. Leukemia. 2001; 15:869-874.
34. Blagosklonny MV. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell cycle. 2007; 6:70-74.
35. Sawada S, Mese H, Sasaki A, Yoshioka N, Matsumura T. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatinresistant human epidermoid carcinoma cell line. Cancer Chemotherapy and Pharmacology. 2003; 51:505-511.
36. Vanlangenakker N, Vanden Berghe T, Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death and Differentiation. 2012; 19:75-86.
37. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, Gillard JW, Jaquith JB, Morris SJ, Barker PA. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Molecular Cell. 2008; 30:689-700.
38. Straub CS. Targeting IAPs as an approach to anti-cancer therapy. Curr Top Med Chem. 2011; 11:291-316.
39. Dutton A, Young LS, Murray PG. The role of cellular FLICE inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer. Expert Opin Ther Targets. 2006; 10:27-35.
40. Shirley S, Micheau O. Targeting c-FLIP in cancer. Cancer Letters. 2013; 332:141-150.
41. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science. 2000; 288:874-877.
42. Hu S, Du MQ, Park SM, Alcivar A, Qu L, Gupta S, Tang J, Baens M, Ye H, Lee TH, Marynen P, Riley JL, Yang X. cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. The Journal of Clinical Investigation. 2006; 116:174-181.
43. Hu S, Yang X. Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. The Journal of biological chemistry. 2003; 278:10055-10060.
44. Chen W, Bai L, Wang X, Xu S, Belinsky SA, Lin Y. Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol Pharmacol. 2010; 77:416-423.
45. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Research. 2010; 70:440-446.
46. Wang Q, Shi S, He W, Padilla MT, Zhang L, Wang X, Zhang B, Lin Y. Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition. Oncotarget. 2014; 5:1304-1314.
47. Wang Q, Chen W, Bai L, Chen W, Padilla MT, Lin AS, Shi S, Wang X, Lin Y. Receptor-interacting protein 1 increases chemoresistance by maintaining inhibitor of apoptosis protein levels and reducing reactive oxygen species through a microRNA-146a-mediated catalase pathway. The Journal of Biological Chemistry. 2014; 289:5654-5663.
48. He W, Wang Q, Xu J, Xu X, Padilla MT, Ren G, Gou X, Lin Y. Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2-and RIPK1/RIP1-mediated MAPK/JNK activation. Autophagy. 2012; 8:1811-1821.